Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBIT (2016 - 2025)

Seres Therapeutics' EBIT history spans 11 years, with the latest figure at -$22.5 million for Q3 2025.

  • For Q3 2025, EBIT rose 22.94% year-over-year to -$22.5 million; the TTM value through Sep 2025 reached -$103.4 million, up 52.8%, while the annual FY2024 figure was -$121.3 million, 37.82% up from the prior year.
  • EBIT for Q3 2025 was -$22.5 million at Seres Therapeutics, up from -$24.9 million in the prior quarter.
  • Across five years, EBIT topped out at $68.4 million in Q3 2021 and bottomed at -$126.6 million in Q4 2023.
  • The 5-year median for EBIT is -$34.4 million (2024), against an average of -$33.3 million.
  • The largest annual shift saw EBIT skyrocketed 328.06% in 2021 before it plummeted 7216.0% in 2023.
  • A 5-year view of EBIT shows it stood at -$49.4 million in 2021, then skyrocketed by 96.5% to -$1.7 million in 2022, then tumbled by 7216.0% to -$126.6 million in 2023, then skyrocketed by 77.23% to -$28.8 million in 2024, then rose by 22.05% to -$22.5 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's EBIT are -$22.5 million (Q3 2025), -$24.9 million (Q2 2025), and -$27.2 million (Q1 2025).